Skip to main content
drug_type
RELEVANT_DRUG
intervention_type
Immunotoxin (cytokine–toxin fusion biologic)
drug_description
Recombinant cytokine–toxin fusion (IL-3 linked to truncated diphtheria toxin) that binds CD123 (IL-3Rα) on AML cells, is internalized, and inhibits protein synthesis via EF-2 ADP-ribosylation to kill CD123+ blasts/progenitors.
nci_thesaurus_concept_id
C64769
nci_thesaurus_preferred_term
Tagraxofusp-erzs
nci_thesaurus_definition
A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration of tagraxofusp-erzs, the IL3 moiety binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. IL3 may be overexpressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML).
drug_mesh_term
Tagraxofusp
drug_category
CYTOTOXIC FUSION PROTEIN
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Recombinant IL-3–diphtheria toxin fusion that binds CD123 (IL-3R alpha) on target cells, is internalized, and the diphtheria toxin catalytic domain ADP-ribosylates EF-2 to halt protein synthesis, leading to death of CD123-positive blasts/progenitors.
drug_name
tagraxofusp-erzs
nct_id_drug_ref
NCT05716009